Recent News

• 08.05.2026 - BioCryst Reports Second Quarter 2026 Financial Results
• 07.22.2026 - BioCryst to Report Second Quarter 2026 Financial Results on August 5
• 07.15.2026 - BioCryst Appoints David W. Jenkins as Chief Scientific Officer
• 07.02.2026 - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.29.2026 - BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
• 06.12.2026 - BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
• 06.09.2026 - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 05.27.2026 - BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
• 05.13.2026 - BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
• 05.06.2026 - BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

Recent Filings

• 08.05.2026 - EX-99.1 EX-99.1
• 08.05.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 08.05.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2026 - 8-K Current report
• 08.04.2026 - 8-K/A Current report
• 06.29.2026 - 8-K Current report
• 06.29.2026 - EX-99.1 EX-99.1
• 06.15.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.15.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.15.2026 - 4 Statement of changes in beneficial ownership of securities